Phase1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX2-73Dec 11, 2014CNS Summit 2014, Boca Raton, FLOle Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher MisslingView Poster
CNS Summit 2014, Boca Raton, FLOle Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher MisslingView Poster
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025